Change of serum ACTH and Cortisol levels in Alzheimer disease and mild cognition impairment

National Medical Journal of China

Volumn 90, Issue 41, 2010, Pages 2894-2896

  Lei, Jian Kang ^a  

^a GUANGZHOU RED CROSS HOSPITAL   (China)

Author keywords

Adreno cortico tropic hormone; Alzheimer disease; Cognitivedeficit; Cortisol

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE;

ALZHEIMER DISEASE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE SEVERITY; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; AGED; BLOOD; CASE CONTROL STUDY; COGNITIVE DEFECT; FEMALE; MALE; MIDDLE AGED;

ADRENOCORTICOTROPIC HORMONE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED;

EID: 84871443417     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.41.004     Document Type: Article

References (10)

1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 1984, 34:939-944.
2. Petersen R C, Stevens J C, Gandulim M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurlogy, 2001, 56:1133-1142.
3. Kulstad J J, McMillan P J, Leverenz J B, et al. Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. Neuropathol Exp Neurol, 2005, 64:139-146.
4. Green K N, Billings L M, Roozendaal B, et al. Glucocorticoids increase amyloid- beta and tau pathology in a mouse model of Alzheimer's disease. Neurosci, 2006, 26:9047-9056.
5. Dai J, Buijs R, Seaab D. Glucocorticoid hormone (Cortisol) affects axonal transport in human cortex neurons but shows resistances in Alzheimer's disease. Br J Pharmacol, 2004, 143:606-610.
6. Elgh E, Lindqvist Astot A, Fagerlund M, et al. Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol Psychiatry, 2006, 59: 155-161.
7. Csernansky J G, Dong H, Fagan A M, et al. Plasma Cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry, 2006, 163:2164-2169.
8. Lind K, Edman A, Nordlund A, et al. Increased saliva Cortisol awakening response in patients with mild cognitive impairment. Dement Geriatr Cogn Disord, 2007, 24:389-395.
9. Martin J S, Joanna P, Henrieta S, et al. Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci USA, 2006, 103:18787-18792.
10. Colton C A, Vitek M P, Wink D A, et al. No synthase 2 deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc Natl Acad, 2006, 103:12867-12872.